137 Ventures Just Raised $700 Million to Bet Bigger on SpaceX. Here's the Risk Retail Investors Miss

137 Ventures just closed more than $700 million across two new funds, pushing its total assets under management past $15 billion. The firm now owns over 1% of SpaceX, a position founder Justin Fishner-Wolfson told Bloomberg Television is "well over $10 billion." That single stake may represent close to two-thirds of the fund's entire AUM. If you're an LP writing a check into 137's next fund, you're not really diversifying into venture. You're taking a leveraged side bet on one rocket company and hoping the rest of the portfolio is gravy.

I've tracked secondaries and NAV-lending shops for years, and 137 Ventures is the cleanest case study I've seen of a strategy that works spectacularly until the one asset it's built around stops cooperating. Let me walk through how this firm built its position, what concentration risk actually costs an LP in dollars and variance, and why the accredited investors trying to copy this trade through secondary marketplaces are buying a much worse version of it.

How 137 Ventures Built a 1% Stake in SpaceX Without Ever Selling a Share

137 Ventures didn't get into SpaceX through a normal primary round. The firm first invested in SpaceX in 2010, when the company was worth roughly $1 billion, and then kept buying. Sourcery's reporting on the position counts approximately 24 follow-on checks over 16 years. 137 has never sold a share of SpaceX. That's the entire strategy in one sentence: buy early, keep buying on every liquidity window that opens up, and never take a distribution off the position no matter how large it gets relative to the rest of the fund. The mechanism for "keep buying" in a company that famously controls its own cap table is what makes 137 Ventures interesting as a firm, not just as a SpaceX bull. Three tools do most of the work.

Secondaries: Buying From People Who Need Cash Now

SpaceX employees and early investors periodically need liquidity, and SpaceX runs structured tender offers rather than letting free-for-all secondary trading happen on the cap table. Firms like 137 position themselves as buyers in those tenders, and separately buy stakes directly from departing employees or smaller funds that need to return capital to their own LPs. Because 137 has been doing this since 2010, it has standing relationships and diligence history that let it move fast when a seller shows up. That's the actual moat: not capital, but incumbency.

NAV Loans: Borrowing Against What You Already Own to Buy More

The second tool is more aggressive. A NAV (net asset value) loan lets a fund borrow against the value of its existing portfolio, using illiquid private stakes as collateral, and then deploy that borrowed cash into new positions, including more of the same company. This is Business Insider's reporting on 137's roughly $6 billion secondaries and lending strategy gets at directly: the firm doesn't just buy stakes, it lends against them and recycles the proceeds. If SpaceX is your best-performing, most liquid-adjacent collateral, it becomes the asset you borrow against most easily, which means it becomes the asset you can buy more of most easily. The position compounds itself. Layer in that 137 deployed more than $1.7 billion over the prior 12 months into companies like Cognition, Impulse Space, Hadrian, and Physical Intelligence, and you can see the pattern: this is a firm underwriting a small number of very large positions in AI, defense, and advanced manufacturing, with SpaceX as the anchor tenant that dwarfs everything else.

What the New $700 Million Actually Buys

The April 2026 raise wasn't one fund. It split into two: a primary-investment and tender vehicle for new deployment, and a separate fund built to give founders and employees of 137's existing 60-plus portfolio companies a way to get liquidity without selling into the open market. That second fund is itself a signal. When a firm needs a dedicated vehicle to buy shares from the employees of the companies it already backs, it's telling you those companies are staying private longer than employees can wait.

Metric	Figure	Source
New capital raised (two funds)	$700M+	PRNewswire, Apr 30 2026
Total AUM after close	$15B+	PRNewswire, Apr 30 2026
Reported SpaceX stake value	"Well over $10B"	Fishner-Wolfson via Bloomberg
SpaceX ownership percentage	1%+	Bloomberg, Apr 30 2026
Capital deployed, trailing 12 months	$1.7B+	TechCrunch, Apr 30 2026
Active portfolio positions	40+ of ~60 backed	Dealroom.co, Sourcery.vc

Look at the top and bottom rows together. A firm with $15 billion in AUM holding a SpaceX position that independent estimates put closer to $20 billion once you account for SpaceX's reported $1.77 trillion expected listing valuation isn't running a diversified fund with a big winner in it. Sourcery's math implies the SpaceX mark alone could exceed the fund's total reported AUM, which only makes sense if 137 is counting the position across multiple fund vintages and reporting AUM net of the debt used to acquire pieces of it. Either way, the headline "$15 billion platform" and the reality "one position worth $10-20 billion" are describing the same firm from two different angles, and only one of those angles is comforting to an LP doing portfolio construction.

What Concentration Risk Actually Means for an LP, in Plain English

Venture capital's entire pitch to LPs for the last three decades has rested on portfolio construction: back 30 to 100 companies, expect most to fail, let the two or three outliers return the fund and then some. That model diversifies away single-company risk. If the winner in your portfolio hits, great. If it stumbles, you've got 29 other shots. 137 Ventures is not that model anymore, and hasn't been for a while. When one asset represents a majority of AUM, the fund's return profile stops being "venture returns" and starts being "SpaceX's IPO outcome, plus some optionality on Anduril, Palantir, and a dozen AI companies." An LP who thought they were buying a diversified growth-stage sleeve is actually buying:

• A leveraged position on SpaceX's IPO timing, price, and lockup structure, since NAV loans mean the fund's balance sheet carries debt against that stake.
• Correlated exposure across the rest of the book, because Anduril, Palantir, and the defense-and-AI names in 137's portfolio move on similar macro and sector triggers as SpaceX. If AI capex sentiment sours or defense-tech valuations reset, the "diversification" among the other 39 positions is thinner than the count suggests.
• Mark-to-model risk. Private company valuations aren't set by daily trading. They're set by the last tender price, the last funding round, or a GP's internal model. A $10 billion SpaceX mark can move a lot before an actual liquidity event tests it.

None of this means 137's LPs made a bad bet. SpaceX at a $1 billion entry valuation in 2010, held through a possible $1.77 trillion listing, is one of the great venture trades of the era if it prices anywhere near that number. My point is narrower: LPs underwriting the next 137 fund need to underwrite SpaceX specifically, not "venture as an asset class," and most fund subscription documents don't make you do that math explicitly. You have to do it yourself, the way I just did above.

Why Retail and Accredited Investors Chasing This Exposure Are Buying a Worse Version of the Same Trade

Every time a story like this breaks, I get some version of the same question: how do I get SpaceX exposure myself? The honest answer is that you mostly can't, not on terms anywhere close to what 137 got, and the paths that exist carry risks that get glossed over in the pitch decks. Secondary marketplaces like Forge Global and EquityZen list interests in SpV wrappers or funds that claim exposure to SpaceX shares. Here's what actually happens when you buy one of those listings, and why each step erodes your position relative to a direct holder like 137.

The Markup Stack

SpaceX doesn't let just anyone buy stock. A retail-adjacent buyer typically ends up several steps removed: an early employee or seed investor sells to a fund, that fund packages the stake into an SPV, a placement platform lists interests in that SPV, and you buy a slice of the SPV. Every layer in that chain takes a fee or a spread. By the time you're the buyer, you're paying a price that reflects the original holder's cost basis, plus the fund's markup, plus the SPV's carry and management fee, plus the platform's placement fee. A stake that cost an early holder pennies on today's dollar can arrive at your desk marked up 30% to 50% over what a direct secondary buyer like 137 would pay in a tender.

Illiquidity and the Bid-Ask Spread Nobody Quotes You

There is no public order book for SpaceX shares. When you buy an SPV interest, you're locked in until the wrapper's manager finds a buyer for the underlying stake, which usually means waiting for SpaceX's next company-run tender window, or waiting for the IPO itself. If you need to exit early, you're selling into a market with maybe a handful of interested counterparties, and the spread between what a seller wants and what a buyer will pay can run into double-digit percentages. Compare that to a 137 Ventures fund, which at least has scale, standing relationships, and years of track record giving it priority access when SpaceX opens a tender.

Information Asymmetry You Can't Diligence Away

137, Founders Fund, and the other long-tenured SpaceX holders have board-adjacent visibility, historical financials, and relationships with the company that inform their entry and hold decisions. You, buying an SPV interest off a placement platform, get a subscription document, a summary of the underlying company's public reporting (which for SpaceX is thin since it's private), and whatever the platform's marketing page tells you about the last known valuation. You are pricing a $1.77 trillion expected-listing valuation off secondhand information while the sellers on the other side of the trade have decades of direct access. That asymmetry doesn't average out with diversification. It's baked into every unit you buy.

What I'd Actually Tell an Accredited Investor Weighing This

If you're determined to get exposure to this trade rather than just admire it from the sidelines, be precise about what you're buying and what you're not.

• Check the SPV's actual chain of title to the underlying SpaceX shares. Ask how many wrapper layers sit between the sponsor and SpaceX's cap table, and what fee each layer takes. If the sponsor won't answer clearly, that's the answer.
• Assume you cannot exit before SpaceX's next tender or its IPO. Size the position as money you can lock up for years, not a trade you can unwind if your thesis changes.
• Compare the SPV's implied valuation against the most recent publicly reported SpaceX tender or funding price. A material premium tells you where the markup stack landed.
• Consider a diversified secondaries fund or fund-of-funds structure instead of a single-company SPV. You give up the SpaceX-specific upside, but you get manager diligence and some spread of risk across positions instead of a single illiquid bet wrapped in fees.
• Read the fine print on any secondary marketplace listing for whether it's an equity interest, a profit-participation right, or a forward contract on a future liquidity event. Those are not the same instrument, and they carry different claims if something goes wrong at the SPV or sponsor level.

The 137 Ventures story is a genuinely great venture outcome sitting inside a genuinely uncomfortable risk profile, and both things are true at the same time. The firm turned a 2010 bet into a stake that could be worth $20 billion. It also built a fund where a huge share of the return now depends on one company's IPO going roughly as planned. If you're an LP, know which fund you're actually in. If you're an accredited investor eyeing the secondary market for a taste of the same trade, know that you're buying several steps and several markups removed from the position 137 spent sixteen years building, and price that distance honestly before you wire money.

Related reading: how feeder funds work, our iCapital Network review, AIN's venture capital coverage.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.